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S200 Poster Session Iof 2-year survival. Summary data regarding histologic subtype,
stage, immune status, viral load at ASCT and conditioning regi-
men will also be presented.
Conclusion: ASCT for HIV(+) patients has a comparable response
and survival to the HIV(-) population for ASCT. Consideration of
ASCT as an earlier therapeutic option in HIV related lymphoma
should be investigated. Additional prospective trials are necessary
to determine optimal management of this population.115
DEFINING THE OPTIMAL THRESHOLD OF PERIPHERAL BLOOD (PB)
CD34 + CELLS TO INITIATE APHERESIS IN PATIENTS WITH NHL UNDER-
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Introduction: PB CD34+ cells are routinely monitored to optimize
the timing and success of CD34+ stem cell collection after G-CSF6
chemotherapy mobilization in NHL patients (pts) undergoing auto-
HSCT.A threshold of#10PBCD34+cells/ml is oftenused topredict
poor mobilization and aid the decision of whether novel therapies
such as plerixafor should be included in the mobilization scheme.
This analysis evaluatedwhether a PB threshold#10 cells/ml is indeed
the most optimal threshold to predict mobilization failure.
Methods:This was a post-hoc analysis of pts with NHL (enrolled in
the phase 3 study 3101) mobilized with G-CSF alone (10 mg/kg SC
for up to 8 doses). PB CD34+ cells were measured on the morning of
Day 4,24H prior to apheresis. The proportion of pts collecting the
minimal ($2  106) or optimal ($5  106) CD34+ cell dose and
apheresis yields were evaluated in pts with PB CD34+ cells/ml #10
(PB #10) or .10 (PB .10).
Results: This analysis was restricted to patients randomized to re-
ceive G-CSF plus placebo. In the 3101 study, 142 pts were mobi-
lized with G-CSF alone; Day 4 PB CD34 cell counts were available
for 124 pts. 75/124 (60%) pts had PB #10 and 49/124 (40%) pts
had PB .10. The median CD34+ cell yield in 2 days was 0.97 
106 cells/kg in pts with PB #10 and 3.3  106 cells/kg in pts
with PB .10. The median CD34+ cell yield in 4 days was 1.31
 106 cells/kg in pts with PB #10 and 4.52  106 cells/kg in pts
with PB .10. Only 22.7% pts with PB #10 and 65.3% pts with
PB .10 collected the minimal cell dose of $2 x106 cells/kg in 2
days. If apheresis was continued for 4 days then 34.7% pts with
PB #10 and 79.6% pts with PB .10 were able to collect the min-
imal dose. Similarly, only 5.3% pts with PB #10 and 30.6% pts
with PB .10 collected the optimal cell dose of $5 x106 cells/kg
in 2 days. Continuing apheresis for 4 days allowed 10.7% patients
with PB #10 and 40.8% patients with PB .10 to collect the opti-
mal dose.
Conclusion:Collectively, these data demonstrate that if apheresis
was planned in pts with .10 PB CD34+ cells/ml, then 20.4% pts
would not collect the minimal cell dose ($2106) and 59.2% pts
would not collect the optimal cell dose ($5106) in 4 apheresis
days. Thus, a threshold of .10 PB CD34+ cells/ml does not en-
sure adequate stem cell collection in a significant proportion of
NHL patients mobilized with G-CSF alone. Higher PB
CD34+ thresholds should be evaluated to ensure effective HSC
collection in NHL pts proceeding to HSCT.
Mobilization Outcomes in G-CSF Mobilized Patients with PB
#10 or PB. 10Median (range) cumulative CD341 cells/
kg x 106 after 2 apheresis days0.97 (0.06 - 9.16) 3.30 (0.46 - 12.00)Median (range) cumulative CD341 cells/
kg x 106 after 4 apheresis days1.31 (0.06 - 10.58) 4.52 (0.46 - 15.00)% Pts achieving $2 x 106 CD341Cells/
Kg in 2 days22.7 65.3% Pts achieving $2 x 106 CD341Cells/
Kg in 4 days34.7 79.6% Pts achieving $5 x 106 CD341Cells/
Kg in 2 days5.3 30.6% Pts achieving $5 x 106 CD341Cells/
Kg in 4 days10.7 40.8116
ADDITION OF BORTEZEMIB TO HIGH DOSE MELPHALAN DOES NOT IM-
PROVE RESPONSE RATE OR PROGRESSION-FREE SURVIVAL
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Background: High dose melphalan remains the preparative regi-
men of choice for autologous hematopoietic stem cell transplan-
tation (auto HCT) in multiple myeloma (MM). Bortezomib is
an active agent in newly diagnosed or relapsed MM, and has syn-
ergistic activity with melphalan. We recently conducted two ran-
domized phase II trials in MM, one of which studied the safety
and efficacy of adding bortezomib to high-dose melphalan in
the preparative regimen for auto HCT. Here we report the re-
sponse rates, progression-free survival (PFS) and overall survival
(OS) between the melphalan-based preparative regimens with or
without bortezomib.
Methods: In the first randomized trial 48 patients received high-
dose Melphalan at 100 mg/m2 IV on days -4 and -3, and ascorbic
acid (AA) 1000 mg IV daily on days -9 to -3. Patients in arm 1
did not receive arsenic trioxide (ATO); patients in arm 2 received
ATO 0.15 mg/kg IV from days -9 to -3; patients in arm 3 re-
ceived ATO at 0.25 mg/kg from days -9 to -3. In the second ran-
domized trial 60 patients were enrolled and 58 received an auto
HCT with a preparative regimen of melphalan 100 mg/m2 IV on
days -4 and -3, AA 1000 mg/day IV on days -9 to -3 and ATO
0.25 mg/kg IV on days -9 to -3. Patients in the second trial were
randomized to 3 arms; no bortezomib (arm 1), bortezomib 1 mg/
m2 on days -9, -6 and -3 (arm 2), and bortezomib 1.5 mg/m2 on
days -9, -6 and -3 (arm 3).
Results: A total of 106 patients received an auto HCT in these 2
trials. Of 106 patients, 39 received a preparative regimen with
bortezomib (Group A) and 67 without bortezomib (Group B). Pa-
tient characteristics and outcome are summarized in Table 1. Pa-
tients in group B (without bortezomib) were slightly older, had
a longer interval between diagnosis and auto HCT and 21%
had a prior auto HCT (vs. 2% in group A). Complete + very
good partial response rates (CR + VGPR) in groups A and B
were similar (31% vs. 31%). Median PFS and OS in group A
vs. B were 14 vs. 23 months (p5 0.08) and 80 vs. 82 months
(p5 0.17), respectively.
Conclusions: In this analysis of 106 patients, adding bortezomib to
a HD melphalan preparative regimen did not improve the response
rate, PFS or OS.
Patient Characteristics and Outcomes
Group A Group B
(Bortezomib) (No Bortezomib)Number of patients 39 67
Median age 59 55
Abnormal cytogenetics 13 11
Relapsed disease 10 25
Prior auto HCT 1 14
Months from diagnosis to auto HCT 9 14
Median CD34 dose 106/kg 3.9 4.56
Median days to engraftment 10 10
Grade 3-4 adverse effects 12 20
CR 7 (18%) 16 (24%)(Continued )
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Total CD341 cells collected 2.09 1.42 0.003CR1VGPR 12 (31%) 22 (31%)
(x106/kg); median (range)Median PFS (months) 14 23Number of patients collecting 14 (37%) 1 (2%) \0.0001Median OS (months) 80 82
2 million CD341 cells in
one apheresis# clinic visits (MD/PA) 2 (0-6) 1 (0-9) 0.15
# days IV antibiotics 0 (0-7) 0 (0-14) 0.1
# inpatient days 0 (0-4) 0 (0-13) 0.02
# RBC units transfused 0 (0-6) 0 (0-11) 0.22
Platelet units transfused 0 (0-24) 0 (0-36) 0.6
# of CBC/diff performed 7 (3-15) 7 (2-27) 0.26
# of comprehensive metabolic
panels performed
2 (0-6) 2 (0-19) 0.94117
LONG TERM SURVIVAL FOLLOWING HIGH DOSE SEQUENTIAL CHEMO-
THERAPYWITH AUTOLOGOUS HEMATOPOIETIC CELL RESCUE FORMUL-
TIPLE MYELOMA
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Sullivan, K.1, Edwards, J.2, Jacobson, R.3, Corbet, K.1, Chao, N.1,
Long, G.1 1Duke University Medical Center, Durham, NC; 2Florida
Hospital, Orlando, FL; 3Palm Beach Cancer Institute, West Palm Beach,
FL
High-dose therapy (HDT) with autologous hematopoietic cell
rescue (AHCR) improves survival in patients with multiple mye-
loma, but is not curative due to a continuous risk of relapse.
One approach to try to reduce relapse is to optimize pretransplant
therapy and the preparative regimen. We investigated the out-
come of sequential HDT with AHCR. Patients were initially
treated with standard dose chemotherapy (primarily VAD) to
maximum response. They then received cyclophosphamide 4
gm/m2 followed by G-CSF and peripheral blood hematopoietic
cell collection by apheresis upon count recovery. They were
then treated with etoposide 2 gm/m2 followed by G-CSF and
apheresis upon count recovery. The transplant preparative regi-
men consisted of carmustine 500 mg/m2 on day -4 and melphalan
200 mg/m2 on day -2 followed by AHCR on day 0. Seventy-six
patients were treated between 1997 and 2001. The patient popu-
lation included 56% males with a median age at transplant of 54
years (range 39-68 years). Forty patients had IgG myeloma, 11 pa-
tients had IgA myeloma, 8 patients had light chain only disease, 5
patients had nonsecretory disease, 1 patient had IgM myeloma and
subtype is unknown in 11 patients. Forty patients were trans-
planted with CD34 selected cells. The Kaplan-Meir estimated me-
dian progression-free survival is 4.2 years (CI 3.1-6.0 years) with
a median overall survival of 7.2 years (CI 4.8-11.4 years). The me-
dian follow up of the 36 surviving patients is 8.46 years with
a range of 4.71 to 11.4 years. One patient was lost to follow up.
The Kaplan-Meir estimated progression-free survival at 10 years
is 35% with overall survival of 45%. Two patients died of inter-
stitial pneumonitis at 21 and 76 days post transplant and two pa-
tients died of secondary leukemia at 694 and 712 days post
transplant. High dose sequential chemotherapy is well tolerated
and results in long term survival in a significant proportion of pa-
tients with multiple myeloma.118
RETROSPECTIVE COMPARISON OF SECONDARY MOBILIZATION STRATE-
GIES IN CANDIDATES FOR AUTOLOGOUS HEMATOPOIETIC CELL TRANS-
PLANTION WITH A FOCUS ON RESOURCE UTILIZATION:
PLERIXAFOR + G-CSF VERSUS OTHER REGIMENS
Perkins, J., Bookout, R., Sapiro, J., Alsina, M., Ayala, E., Field, T.L.,
Kharfan-Dabaja, M.A., Perez, L.E., Ochoa-Bayona, J.L.,
Tomblyn, M., Daily, K., Elstner, C., Anasetti, C., Fernandez, H.F. Mof-
fitt Cancer Center, Tampa, FL
Successful autologous transplantation relies on hematopoietic cell
mobilization that allows adequate CD34+ cell collection. Depite ap-
propriate mobilization approaches, a significant number of patients
(pts) do not mobilize adequate CD34+ cells and require a second
round of mobilization therapy. We performed a retrospective analy-
sis of our experience with different secondary mobilization strategies
with a focus on resource utilization. Primary endpoint was compar-ing plerixafor versus other regimens with respect to the rate of suc-
cessful second mobilization defined as the ability to collect at least
2106 CD34+ cells/kg (cumulative). Included here are 96 pts receiv-
ing their primary mobilization therapy between 2000-09. Pts are di-
vided into two groups depending on the secondary mobilization
therapy given: Plerixafor + G-CSF (PG; n5 38) or Other (OTH;
n5 58). which included chemotherapy +G-CSF in 15 pts, G-CSF
alone in 23 pts or G-CSF andGM-CSF in 20 pts. There were no dif-
ferences in pt characteristics between the two groups except for
a higher number of non-Hodgkin’s lymphoma pts in the PG group
and more pts with multiple myeloma in the OTH group. In the
PG mobilized group, 29% were first mobilized with chemothera-
py +G-CSF and 71% were mobilized with G-CSF alone. In the
OTH pts, 41% received chemotherapy +G-CSF, 43% G-CSF
alone, and 16% G-CSF +GM-CSF. Median numbers of CD34+
cells (x 106/kg) collected after the first mobilization were 0.39 (0-
1.76) in the PG pts and 0.56 (0-2.08) in the OTH pts. Pts in the
PG group received a median of 2 doses of plerixafor (range 1-4) dur-
ing their second mobilization regimen. Eight of the 38 PG pts were
enrolled on clinical trials requiring at least 2 doses of plerixafor and
a minimum of 2 aphereses. Outcomes following the second mobili-
zation and resource utilization from the first day of second
mobilization to the last day of pheresis are shown below. Thirty-
two of the 38 PG pts (84%) were able to collect a total of at least 2
 106 CD34+ cells/kg from both mobilizations to proceed to trans-
plant; this is compared to 47/58 (80%) in theOTHgroup (p5 0.62).
Of those pts that were transplanted, there were no differences in time
to neutrophil or platelet recovery. The current data suggest that
when using plerixafor plus G-CSF in this setting there is a potential
for significant cost savings based on the reduced apheresis and hos-
pitalization requirements when compared to other forms of mobili-
zation.119
QUALITY OF UMBILICAL CORD BLOODUNITS STORED FOR AUTOLOGOUS
USE AND INFUSED INTRAVENOUSLY IN CHILDREN WITH ACQUIRED
NEUROLOGICAL CONDITIONS
Sun, J., Allison, J., McLaughlin, C., Sledge, L., Waters-Pick, B.,
Kurtzberg, J. Duke University, Durham, NC
Background: Numerous animal models demonstrate neurological
and survival benefits of bone marrow or umbilical cord blood (CB)
infusion in the setting of stroke, thermal injury, ischemia, intracra-
nial hemorrhage and spinal cord injury. Based on these data, we ini-
tiated a pilot study to determine the safety and feasibility of
intravenous (IV) administration of autologous CB (aCB) in young
children with acquired neurological disorders. Most units were elec-
tively stored in private CB banks at the request and expense of the
